title: Advances in sickle cell disease treatment: from drug discovery until the patient monitoring.
abstract: Sickle cell disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed.
authors.affiliation: Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas- Universidade Estadual Paulista, Rodovia Araraquara Jaú Km. 01, Araraquara, SP, Brazil. santosjl@fcfar.unesp.br
authors.forename: Jean Leandro
authors.initials: JL
authors.lastname: dos Santos
authors.forename: Carolina
authors.initials: C
authors.lastname: Lanaro
authors.forename: Chung Man
authors.initials: CM
authors.lastname: Chin
mesh_terms: D000755:Anemia, Sickle Cell / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D000986:Antisickling Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery / Q000379:methods; D004912:Erythrocytes / Q000187:drug effects / Q000473:pathology; D006454:Hemoglobins / Q000378:metabolism; D018056:Hemorheology / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology / Q000627:therapeutic use; D009569:Nitric Oxide / Q000378:metabolism; D028321:Plant Preparations / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000986:Antisickling Agents; D002614:Chelating Agents; D006454:Hemoglobins; D028321:Plant Preparations; D009569:Nitric Oxide; D006918:Hydroxyurea